Literature DB >> 11786417

Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.

Bénédicte Chazaud1, Rémy Ricoux, Christo Christov, Anne Plonquet, Romain K Gherardi, Georgia Barlovatz-Meimon.   

Abstract

The urokinase-type plasminogen activator (uPA) system is a dynamic complex in which the membrane receptor uPAR binds uPA that binds the plasminogen activator inhibitor (PAI)-1 localized in the extracellular matrix, resulting in endocytosis of the whole complex by the low-density lipoprotein receptor-related protein (LRP). High expression of PAI-1 is paradoxically associated with marked tumor spreading and poor prognosis. We previously reported a nonproteolytic role of the [uPAR:uPA:PAI-1:LRP] complex operative in cell migration. Here we explored whether matrix PAI-1 could be used as a migration support by human breast cancer cells. We showed that the uPA system and LRP are localized at filopodia of invasive cells, and that formation/internalization of the [uPAR:uPA:PAI-1:LRP] complex is required for attachment and migration of cancer cells on plastic and on a PAI-1 coat. PAI-1 increased both filopodia formation and migration of cancer cells suggesting a chemokine-like activity. Migration velocity, expression of the uPA system, use of the [uPAR:uPA:PAI-1:LRP] complex to migrate, and promigratory effects of PAI-1 paralleled cancer cell invasiveness. Phenotyping and functional analysis of invasive cancer cell subclones indicated that different cell subpopulations may use different strategies to migrate depending on both the environment and their expression of the uPA system, some of them taking advantage of abundant available PAI-1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786417      PMCID: PMC1867133          DOI: 10.1016/S0002-9440(10)64367-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

1.  Autocrine saturation of pro-urokinase receptors on human A431 cells.

Authors:  M P Stoppelli; C Tacchetti; M V Cubellis; A Corti; V J Hearing; G Cassani; E Appella; F Blasi
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

2.  Regulation of urokinase receptor transcription by Ras- and Rho-family GTPases.

Authors:  S M Muller; E Okan; P Jones
Journal:  Biochem Biophys Res Commun       Date:  2000-04-21       Impact factor: 3.575

3.  The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis.

Authors:  S Mukhina; V Stepanova; D Traktouev; A Poliakov; R Beabealashvilly; Y Gursky; M Minashkin; A Shevelev; V Tkachuk
Journal:  J Biol Chem       Date:  2000-06-02       Impact factor: 5.157

4.  Breast tumor cell lines from pleural effusions.

Authors:  R Cailleau; R Young; M Olivé; W J Reeves
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

Review 5.  Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth.

Authors:  L Ossowski; J A Aguirre-Ghiso
Journal:  Curr Opin Cell Biol       Date:  2000-10       Impact factor: 8.382

6.  Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility.

Authors:  B Chazaud; S Bonavaud; A Plonquet; M Pouchelet; R K Gherardi; G Barlovatz-Meimon
Journal:  Exp Cell Res       Date:  2000-08-01       Impact factor: 3.905

7.  Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.

Authors:  S Huang; L New; Z Pan; J Han; G R Nemerow
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

8.  Examination of the function of RANTES, MIP-1alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans.

Authors:  S Ali; A C Palmer; B Banerjee; S J Fritchley; J A Kirby
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

9.  Receptor-mediated endocytosis of CC-chemokines.

Authors:  R Solari; R E Offord; S Remy; J P Aubry; T N Wells; E Whitehorn; T Oung; A E Proudfoot
Journal:  J Biol Chem       Date:  1997-04-11       Impact factor: 5.157

10.  Very low density lipoprotein receptor from mammary gland and mammary epithelial cell lines binds and mediates endocytosis of M(r) 40,000 receptor associated protein.

Authors:  A C Simonsen; C W Heegaard; L K Rasmussen; L Ellgaard; L Kjøller; A Christensen; M Etzerodt; P A Andreasen
Journal:  FEBS Lett       Date:  1994-11-14       Impact factor: 4.124

View more
  33 in total

1.  LRP-1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities.

Authors:  Stéphane Dedieu; Benoît Langlois; Jérôme Devy; Brice Sid; Patrick Henriet; Hervé Sartelet; Georges Bellon; Hervé Emonard; Laurent Martiny
Journal:  Mol Cell Biol       Date:  2008-03-03       Impact factor: 4.272

Review 2.  LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies.

Authors:  Anna P Lillis; Lauren B Van Duyn; Joanne E Murphy-Ullrich; Dudley K Strickland
Journal:  Physiol Rev       Date:  2008-07       Impact factor: 37.312

3.  Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9.

Authors:  Heesang Song; Yonghe Li; Jiyeon Lee; Alan L Schwartz; Guojun Bu
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

4.  ADAM12 and alpha9beta1 integrin are instrumental in human myogenic cell differentiation.

Authors:  Peggy Lafuste; Corinne Sonnet; Bénédicte Chazaud; Patrick A Dreyfus; Romain K Gherardi; Ulla M Wewer; François-Jérôme Authier
Journal:  Mol Biol Cell       Date:  2004-12-01       Impact factor: 4.138

Review 5.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

6.  Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing.

Authors:  François Maquerlot; Stephane Galiacy; Michel Malo; Christophe Guignabert; Daniel A Lawrence; Maria-Pia d'Ortho; Georgia Barlovatz-Meimon
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

7.  Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.

Authors:  Maria U Rømer; Lise Larsen; Hanne Offenberg; Nils Brünner; Ulrik A Lademann
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

8.  SERPINE1 (PAI-1) is deposited into keratinocyte migration "trails" and required for optimal monolayer wound repair.

Authors:  Kirwin M Providence; Stephen P Higgins; Andrew Mullen; Ashley Battista; Rohan Samarakoon; Craig E Higgins; Cynthia E Wilkins-Port; Paul J Higgins
Journal:  Arch Dermatol Res       Date:  2008-04-02       Impact factor: 3.017

9.  Repression of Ah receptor and induction of transforming growth factor-beta genes in DEN-induced mouse liver tumors.

Authors:  Li Peng; Christopher N Mayhew; Michael Schnekenburger; Erik S Knudsen; Alvaro Puga
Journal:  Toxicology       Date:  2008-01-16       Impact factor: 4.221

10.  Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1.

Authors:  Jennifer C Carter; Frank C Church
Journal:  PPAR Res       Date:  2009-08-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.